Trials 56 items

Studies

• Design and rationale of Lp(a)HORIZON, the first Lp(a) outcomes trial: pelacarsen in 8,323 patients (Cho, Nicholls, Nordestgaard et al., Am Heart J 2025)Am Heart J · September 2025 9
• How much Lp(a) lowering equals 1 mmol/L of LDL-C? The Mendelian randomisation answer (Burgess et al., JAMA Cardiol 2018)JAMA Cardiol · July 2018 9
• Alirocumab-induced Lp(a) lowering independently predicts fewer MACE after ACS: ODYSSEY OUTCOMES (Bittner et al., JACC 2020)J Am Coll Cardiol · January 2020 8
• How much Lp(a) lowering for a clinically relevant CHD reduction? The Lp(a)-GWAS-Consortium estimate (Lamina and Kronenberg, JAMA Cardiol 2019)JAMA Cardiol · June 2019 8
• Lp(a), PCSK9 inhibition and cardiovascular risk in FOURIER (O'Donoghue et al., Circulation 2019)Circulation · March 2019 8
• Lp(a) predicts coronary events but not stroke, and evolocumab benefits at any Lp(a): VESALIUS-CV (Monguillon et al., Circulation 2026)Circulation · June 2026 7
• Safety of low Lp(a): no excess of bleeding, malignancy, neurocognitive events or AF, but more diabetes: FOURIER (Gencer et al., EHJ 2026)Eur Heart J · June 2026 7
• Only 13 percent of coronary patients worldwide would meet a 150 nmol/L trial threshold: INTERASPIRE (Barkas et al., JACC 2025)J Am Coll Cardiol · June 2025 7
• Lp(a) lowering by alirocumab reduces total cardiovascular events independent of LDL-C: ODYSSEY OUTCOMES (Szarek et al., EHJ 2020)Eur Heart J · November 2020 7
• Lp(a) lowering of about 50 mg/dL may be needed for a 20 percent MACE reduction in secondary prevention (Madsen et al., ATVB 2020)Arterioscler Thromb Vasc Biol · January 2020 7
• mg/dL to nmol/L: the Copenhagen formula beats the factor 2.5 in the Lp(a)HORIZON screening population (Atherosclerosis 2026)Atherosclerosis · July 2026 6
• Oxidised phospholipids on apoB predict MACE after ACS and alirocumab abolishes the relation: ODYSSEY OUTCOMES (Tsimikas et al., Circulation 2025)Circulation · December 2025 6
• Lp(a) reduction from PCSK9 inhibition does not independently lower cardiovascular events, a pooled analysis of 10 phase 3 alirocumab trials in 4983 patients (Atherosclerosis 2019)Atherosclerosis · June 2019 9
• PCSK9 inhibition lowers LDL cholesterol and Lp(a) discordantly in 20% of patients, a pooled analysis of 4 phase 3 evolocumab trials in 895 patients (J Am Heart Assoc 2019)J Am Heart Assoc · February 2019 8
• PCSK9 monoclonal antibodies cut Lp(a) by 21.9% on average across 27 trials and 11,864 patients (Am J Cardiovasc Drugs 2019)Am J Cardiovasc Drugs · February 2019 8
• Niacin-laropiprant lowers Lp(a) by just 18% in patients with the highest baseline Lp(a) and small isoforms, an HPS2-THRIVE substudy of 3978 patients (Circ Genom Precis Med 2018)Circ Genom Precis Med · February 2018 8
• Alirocumab sustainably lowers Lp(a) by up to 29% over 1.5 years, a pooled analysis of 10 phase 3 ODYSSEY trials in 4915 patients (Am J Cardiol 2017)Am J Cardiol · September 2016 8
• Evacetrapib cuts Lp(a) by up to 40% alone and small LDL particles by up to 95%, a randomised trial of 393 patients (J Clin Lipidol 2016)J Clin Lipidol · December 2015 8
• Evolocumab cuts Lp(a) by up to 29.5%, a pooled analysis of 4 phase 2 trials and 1359 patients (J Am Coll Cardiol 2014)J Am Coll Cardiol · February 2014 8
• Niacin lowers Lp(a) by 21% but does not reduce cardiovascular events, the AIM-HIGH trial analysis of apolipoproteins and Lp(a) (J Am Coll Cardiol 2013)J Am Coll Cardiol · August 2013 8
• AMG145 (evolocumab) cuts Lp(a) by up to 32% in statin-treated patients, the LAPLACE-TIMI 57 phase 2 trial of 631 patients (Circulation 2013)Circulation · July 2013 8
• Lp(a) rises marginally but stays within risk categories after STEMI and does not associate with infarct size in the ASSAIL-MI trial (Atherosclerosis 2026)Atherosclerosis · September 2026 7
• Lp(a) concentrations vary considerably over 24 months in high cardiovascular risk patients with hypertriglyceridemia on statins (REDUCE-IT) (J Clin Lipidol 2026)J Clin Lipidol · September 2026 7
• Lp(a) prevalence and screening thresholds vary across high-risk groups in the Rotterdam Study (Eur J Prev Cardiol 2026)Eur J Prev Cardiol · August 2026 7
• Lp(a)FRONTIERS EXPANSION enrols 422 Black and Hispanic patients for a pelacarsen trial, ahead of schedule (Am J Prev Cardiol 2026)Am J Prev Cardiol · February 2026 7
• PCSK9 inhibitors lower Lp(a) by 15-30%, and FOURIER shows most benefit in patients with high baseline Lp(a), a review (Curr Opin Lipidol 2019)Curr Opin Lipidol · December 2019 7
• Tibolone lowers Lp(a) by up to 29% depending on dose, a meta-analysis of 12 trials and 1009 postmenopausal women (Atherosclerosis 2015)Atherosclerosis · July 2015 7
• The thyroid hormone drug eprotirome cuts LDL cholesterol by up to 31% and lowers Lp(a), a randomised trial of 98 patients (J Intern Med 2015)J Intern Med · May 2014 7
• Atorvastatin lowers Lp(a) more than simvastatin, but neither affects apo(a) fragments, a double-blind trial of 391 patients (Atherosclerosis 2002)Atherosclerosis · October 2002 7
• Full-dose almonds lower Lp(a) by 7.8% alongside oxidized LDL, a crossover trial of 27 people (Circulation 2002)Circulation · September 2002 7
• Olezarsen reduces Lp(a)-associated triglycerides and cholesterol by 56% to 70% without lowering plasma Lp(a) (JACC Basic Transl Sci 2026)JACC Basic Transl Sci · September 2026 6
• Kylo-11 reduces lipoprotein(a) by up to 97 percent at 48 weeks in a phase 1 trial (Lancet 2026)Lancet · August 2026 6
• Lepodisiran advances to phase 3 ACCLAIM-Lp(a) outcomes trial, updated review (Cardiol Rev 2026)Cardiol Rev · March 2026 6
• Conjugated linoleic acid supplements raise both CRP and Lp(a) levels, a meta-analysis of 21 randomised trials (Iran J Med Sci 2019)Iran J Med Sci · September 2019 6
• L-carnitine and coenzyme Q10 emerge as the most promising Lp(a)-lowering supplements, a review of 152 articles (Clin Ther 2019)Clin Ther · July 2019 6
• Ezetimibe does not lower Lp(a), a meta-analysis of 10 randomised trials and 5188 patients (Sci Rep 2018)Sci Rep · December 2018 6
• Ezetimibe modestly lowers Lp(a) by 7.06%, with no clear clinical relevance, a meta-analysis of 7 trials and 2337 patients (Drugs 2018)Drugs · March 2018 6
• Lp(a) varies by more than 25% at some point in 40% of placebo patients in antisense trials, a temporal variability study of 52 subjects (J Clin Lipidol 2018)J Clin Lipidol · November 2017 6
• Soy isoflavones do not affect Lp(a) levels, a meta-analysis of 10 trials and 973 subjects (J Clin Lipidol 2018)J Clin Lipidol · October 2017 6
• Coffee lowers Lp(a) by up to 11 mg/dL short-term, but boiled coffee raises it long-term, a systematic review of 9 trials and 640 participants (Crit Rev Food Sci Nutr 2018)Crit Rev Food Sci Nutr · August 2017 6
• Tamoxifen significantly lowers Lp(a), a meta-analysis of 5 studies and 215 participants (Drugs 2017)Drugs · July 2017 6
• Raloxifene lowers Lp(a), with the effect fading over longer treatment duration, a meta-analysis of 7 trials in postmenopausal women (Cardiovasc Drugs Ther 2017)Cardiovasc Drugs Ther · April 2017 6
• Oral hormone replacement therapy lowers Lp(a) by about 20%, but tibolone does not, a meta-analysis of 24 studies in postmenopausal women (Maturitas 2017)Maturitas · February 2017 6
• Fibrates lower Lp(a) more than statins, and adding fibrates boosts statins effect, a meta-analysis of 16 head-to-head trials and 1388 patients (BMC Med 2017)BMC Med · February 2017 6
• Adding L-carnitine to simvastatin modestly lowers Lp(a) by 19%, a randomised trial of two 29-patient groups (Lipids 2017)Lipids · December 2016 6
• Extended-release niacin lowers Lp(a) by about 23% regardless of dose, a meta-analysis of 14 trials and 9013 patients (Metabolism 2016)Metabolism · August 2016 6
• The only controlled trial of Lp(a)-specific apheresis showed plaque regression after 18 months, a review of Lp(a) apheresis (Curr Opin Lipidol 2016)Curr Opin Lipidol · August 2016 6
• Coenzyme Q10 modestly lowers Lp(a) but not other lipids, a meta-analysis of 7 trials and 409 patients (Pharmacol Res 2016)Pharmacol Res · February 2016 6
• Oral L-carnitine lowers Lp(a) by 9 mg/dL, but intravenous administration does not, a meta-analysis of randomised trials (Sci Rep 2016)Sci Rep · January 2016 6
• Garlic raises Lp(a) by 55% with long-term use over 12 weeks, though short-term use has no effect, a meta-analysis of 6 trials (Nutrition 2016)Nutrition · July 2015 6
• A randomised sham-controlled crossover trial will test whether apheresis helps refractory angina patients with high Lp(a), a study protocol (Atheroscler Suppl 2015)Atheroscler Suppl · May 2015 6
• Vitamin C supplementation does not lower Lp(a), a randomised trial of 101 people over 8 months (Atherosclerosis 2000)Atherosclerosis · August 2000 6
• Garlic supplements have no effect on Lp(a), a randomised trial of 50 hypercholesterolaemic patients (J Am Coll Cardiol 2000)J Am Coll Cardiol · February 2000 6
• Replacing saturated fat with walnuts or vegetable oils improves cholesterol without raising Lp(a), a 34-person crossover trial (J Nutr 2020)J Nutr · April 2020 5
• Phytosterol supplements modestly lower Lp(a), a meta-analysis of 7 randomised trials (Nutr Metab Cardiovasc Dis 2019)Nutr Metab Cardiovasc Dis · July 2019 5
• Evolocumab lowers Lp(a) by 23.6 percent in patients with heterozygous familial hypercholesterolemia (Atheroscler Plus 2026)Atheroscler Plus · June 2026 4